BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15917662)

  • 1. Association of caspase-2 with the promyelocytic leukemia protein nuclear bodies.
    Tang J; Xie W; Yang X
    Cancer Biol Ther; 2005 Jun; 4(6):645-9. PubMed ID: 15917662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are promyelocytic leukaemia protein nuclear bodies a scaffold for caspase-2 programmed cell death?
    Sanchez-Pulido L; Valencia A; Rojas AM
    Trends Biochem Sci; 2007 Sep; 32(9):400-6. PubMed ID: 17693089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of nuclear bodies in apoptosis signalling.
    Krieghoff-Henning E; Hofmann TG
    Biochim Biophys Acta; 2008 Nov; 1783(11):2185-94. PubMed ID: 18680765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
    Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
    Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
    Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
    Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
    Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.
    Reineke EL; Kao HY
    Int J Biol Sci; 2009 May; 5(4):366-76. PubMed ID: 19471587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient mutations alter ATRX targeting to PML nuclear bodies.
    Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
    Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-step colocalization of MORC3 with PML nuclear bodies.
    Mimura Y; Takahashi K; Kawata K; Akazawa T; Inoue N
    J Cell Sci; 2010 Jun; 123(Pt 12):2014-24. PubMed ID: 20501696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
    Roussigne M; Cayrol C; Clouaire T; Amalric F; Girard JP
    Oncogene; 2003 Apr; 22(16):2432-42. PubMed ID: 12717420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
    Frappier L
    Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.
    Bernardi R; Pandolfi PP
    Nat Rev Mol Cell Biol; 2007 Dec; 8(12):1006-16. PubMed ID: 17928811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death-domain associated protein-6 (DAXX) mediated apoptosis in hantavirus infection is counter-balanced by activation of interferon-stimulated nuclear transcription factors.
    Khaiboullina SF; Morzunov SP; Boichuk SV; Palotás A; St Jeor S; Lombardi VC; Rizvanov AA
    Virology; 2013 Sep; 443(2):338-48. PubMed ID: 23830076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage.
    Conlan LA; McNees CJ; Heierhorst J
    Oncogene; 2004 Jan; 23(1):307-10. PubMed ID: 14712236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of component exchange at PML nuclear bodies.
    Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
    J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
    Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
    Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TTRAP is a novel PML nuclear bodies-associated protein.
    Xu GL; Pan YK; Wang BY; Huang L; Tian L; Xue JL; Chen JZ; Jia W
    Biochem Biophys Res Commun; 2008 Oct; 375(3):395-8. PubMed ID: 18706885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral genomes in association with ND10 in live-infected cells.
    Sourvinos G; Tavalai N; Berndt A; Spandidos DA; Stamminger T
    J Virol; 2007 Sep; 81(18):10123-36. PubMed ID: 17626080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein.
    Qin Q; Inatome R; Hotta A; Kojima M; Yamamura H; Hirai H; Yoshizawa T; Tanaka H; Fukami K; Yanagi S
    J Cell Biol; 2006 Feb; 172(4):497-504. PubMed ID: 16461359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.